Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc., has closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib...